tiprankstipranks
Trending News
More News >
Bioxcel Therapeutics (BTAI)
:BTAI
US Market

Bioxcel Therapeutics (BTAI) Ratios

Compare
1,458 Followers

Bioxcel Therapeutics Ratios

BTAI's free cash flow for Q1 2025 was $1.00. For the 2025 fiscal year, BTAI's free cash flow was decreased by $ and operating cash flow was $-43.18. See a summary of the company’s cash flow.
Ratios
TTM
Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio
6.17 2.65 6.17 13.98 18.33
Quick Ratio
6.11 2.57 6.11 13.98 18.33
Cash Ratio
5.89 2.39 5.89 13.98 18.00
Solvency Ratio
-1.33 -1.37 -1.33 -5.98 -6.18
Operating Cash Flow Ratio
-4.11 -5.68 -4.11 -4.93 -5.60
Short-Term Operating Cash Flow Coverage
0.00 0.00 0.00 0.00 0.00
Net Current Asset Value
$ 73.79M$ -58.07M$ 73.79M$ 215.20M$ 203.82M
Leverage Ratios
Debt-to-Assets Ratio
0.46 1.38 0.46 <0.01 <0.01
Debt-to-Equity Ratio
1.23 -1.79 1.23 <0.01 <0.01
Debt-to-Capital Ratio
0.55 2.26 0.55 <0.01 <0.01
Long-Term Debt-to-Capital Ratio
0.55 2.28 0.55 <0.01 <0.01
Financial Leverage Ratio
2.68 -1.30 2.68 1.08 1.06
Debt Service Coverage Ratio
-19.90 -12.42 -19.90 -2.67K -3.03K
Interest Coverage Ratio
-19.44 -12.90 -19.44 -2.67K -3.05K
Debt to Market Cap
<0.01 0.07 <0.01 <0.01 <0.01
Interest Debt Per Share
3.65 3.94 3.65 0.05 0.08
Net Debt to EBITDA
0.63 -0.22 0.63 2.16 2.58
Profitability Margins
Gross Profit Margin
94.67%8.70%94.67%0.00%0.00%
EBIT Margin
-42011.73%-12010.07%-42011.73%0.00%0.00%
EBITDA Margin
-41969.07%-11987.03%-41969.07%0.00%0.00%
Operating Profit Margin
-42572.00%-12447.97%-42572.00%0.00%0.00%
Pretax Profit Margin
-44201.87%-12974.86%-44201.87%0.00%0.00%
Net Profit Margin
-45826.40%-12974.86%-45826.40%0.00%0.00%
Continuous Operations Profit Margin
-44201.87%-12974.86%-44201.87%0.00%0.00%
Net Income Per EBT
103.68%100.00%103.68%99.72%99.80%
EBT Per EBIT
103.83%104.23%103.83%100.00%99.84%
Return on Assets (ROA)
-83.48%-242.94%-83.48%-44.53%-37.29%
Return on Equity (ROE)
-223.83%316.86%-223.83%-48.10%-39.68%
Return on Capital Employed (ROCE)
-92.30%-369.94%-92.30%-48.00%-39.55%
Return on Invested Capital (ROIC)
-95.52%-367.20%-95.52%-47.80%-39.43%
Return on Tangible Assets
-83.48%-242.94%-83.48%-44.53%-37.29%
Earnings Yield
-1.78%-13.02%-1.78%-1.24%-0.51%
Efficiency Ratios
Receivables Turnover
1.51 19.44 1.51 0.00 0.00
Payables Turnover
<0.01 0.09 <0.01 0.06 0.05
Inventory Turnover
0.01 0.63 0.01 0.00 0.00
Fixed Asset Turnover
0.18 0.94 0.18 0.00 0.00
Asset Turnover
<0.01 0.02 <0.01 0.00 0.00
Working Capital Turnover Ratio
<0.01 0.01 <0.01 0.00 0.00
Cash Conversion Cycle
-150.19K -3.36K -150.19K -5.75K -7.73K
Days of Sales Outstanding
241.39 18.78 241.39 0.00 0.00
Days of Inventory Outstanding
36.23K 576.76 36.23K 0.00 0.00
Days of Payables Outstanding
186.66K 3.96K 186.66K 5.75K 7.73K
Operating Cycle
36.47K 595.54 36.47K 0.00 0.00
Cash Flow Ratios
Operating Cash Flow Per Share
-4.83 -5.32 -4.83 -3.12 -3.06
Free Cash Flow Per Share
-4.84 -5.32 -4.84 -3.13 -3.07
CapEx Per Share
<0.01 <0.01 <0.01 0.02 0.01
Free Cash Flow to Operating Cash Flow
1.00 1.00 1.00 1.01 1.00
Dividend Paid and CapEx Coverage Ratio
-973.68 -7.75K -973.68 -184.61 -209.97
Capital Expenditure Coverage Ratio
-973.68 -7.75K -973.68 -184.61 -209.97
Operating Cash Flow Coverage Ratio
-1.44 -1.53 -1.44 -58.76 -40.58
Operating Cash Flow to Sales Ratio
-360.91 -112.32 -360.91 0.00 0.00
Free Cash Flow Yield
-1.41%-11.28%-1.41%-0.96%-0.42%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
-56.03 -7.68 -56.03 -80.45 -195.45
Price-to-Sales (P/S) Ratio
25.68K 996.30 25.68K 0.00 0.00
Price-to-Book (P/B) Ratio
125.41 -24.33 125.41 38.70 77.54
Price-to-Free Cash Flow (P/FCF) Ratio
-71.07 -8.87 -71.07 -103.86 -240.42
Price-to-Operating Cash Flow Ratio
-71.14 -8.87 -71.14 -104.42 -241.57
Price-to-Earnings Growth (PEG) Ratio
-1.08 -23.54 -1.08 -11.70 -2.17
Price-to-Fair Value
125.41 -24.33 125.41 38.70 77.54
Enterprise Value Multiple
-60.54 -8.53 -60.54 -78.01 -192.93
Enterprise Value
9.53B 1.41B 9.53B 8.35B 15.82B
EV to EBITDA
-60.54 -8.53 -60.54 -78.01 -192.93
EV to Sales
25.41K 1.02K 25.41K 0.00 0.00
EV to Free Cash Flow
-70.33 -9.10 -70.33 -101.06 -237.25
EV to Operating Cash Flow
-70.40 -9.10 -70.40 -101.60 -238.38
Tangible Book Value Per Share
2.74 -1.94 2.74 8.41 9.53
Shareholders’ Equity Per Share
2.74 -1.94 2.74 8.41 9.53
Tax and Other Ratios
Effective Tax Rate
-0.04 0.00 -0.04 <0.01 <0.01
Revenue Per Share
0.01 0.05 0.01 0.00 0.00
Net Income Per Share
-6.13 -6.15 -6.13 -4.04 -3.78
Tax Burden
1.04 1.00 1.04 1.00 1.00
Interest Burden
1.05 1.08 1.05 1.00 1.00
Research & Development to Revenue
243.30 61.11 243.30 0.00 0.00
SG&A to Revenue
183.36 46.02 183.36 0.00 0.00
Stock-Based Compensation to Revenue
46.23 13.49 46.23 0.00 0.00
Income Quality
0.82 0.87 0.82 0.77 0.81
Currency in USD
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis